RPS14 as spermatogenesis disorder testis early aging marker for male at childbearing age and application of RPS14

By identifying and verifying the upregulation of RPS14 in the testicles of spermatogenic disorder in childbearing age, a kit for detecting RPS14 expression levels has been developed, which solves the diagnostic problem of premature aging of spermatogenic disorder in male childbearing age, and provides a potential therapeutic target and An efficient diagnostic tool.

CN118995915APending Publication Date: 2024-11-22RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411149345.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to accurately identify and diagnose the premature aging state of testicles in male spermatogenesis disorders in childbearing age, and lacks effective biomarkers and therapeutic targets.

Method used

By studying and verifying that RPS14, as a pro-aging gene upregulated in aging testicles, has significantly upregulated in the testicles of spermatogenesis disorders in childbearing age, a kit for detecting RPS14 expression levels is developed to diagnose premature aging in the testicles, and 探究其与临床、病理和免疫模式的相关性。

Benefits of technology

RPS14 has been identified as an important biomarker for early onset changes in testicles due to spermatogenesis disorders in childbearing age. It has high diagnostic value and potential therapeutic target potential. It can effectively predict the success rate of testicular spermatogenesis and is closely related to the testicular immune microenvironment. Related.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995915A_ABST
    Figure CN118995915A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological detection, and provides RPS14 as a spermatogenesis disorder testis early aging marker for male at childbearing age and application of the RPS14 as the spermatogenesis disorder testis early aging marker. The invention explores and determines a biomarker for early change of testis senescence related gene (SAG) in fertility-age dyszoospermia, identifies and verifies the testis functional SAG RPS14, and the expression of the testis functional SAG RPS14 in old testis and young dyszoospermia testis is significantly changed and is significantly related to clinical pathological characteristics (such as JS and FSH) and testis immune microenvironment of patients. Besides, experiments find that the expression of the biomarker in the old testis and the young spermatogenesis disorder testis has obvious cell specificity, and the cell distribution of the biomarker in the old testis and the young spermatogenesis disorder testis has similar characteristics. A potential diagnostic marker (detection kit) and a possible treatment target can be provided for young patients suffering from male infertility.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological detection technology, and more particularly to the use of RPS14 as a target in the detection of premature testicular aging in spermatogenic disorders in males of childbearing age, and more particularly to the use of a reagent for detecting the expression level of RPS14 in the preparation of a kit for premature testicular aging in spermatogenic disorders in males of childbearing age. Background Art

[0002] As the basis of male reproduction, the most important function of the testicle is spermatogenesis. However, for many young men of childbearing age, they suffer from spermatogenesis dysfunction (which means that the testicular spermatogenesis function is impaired to varying degrees), which is one of the main causes of male infertility. [1] Among these young patients with spermatogenic dysfunction, the most severe form is non-obstructive azoospermia (NOA), which seriously impairs men's physical and mental health and directly leads to male infertility. In order to accurately assess the degree of testicular damage in these patients, pathologists and andrologists widely use the Johnsen score or the modified Johnsen score (abbreviated as JS) [2,3] However, this scoring system is basically based on phenotype, which not only requires long-term specialized pathology training to achieve, but also has shortcomings such as strong subjectivity and inability to explain the underlying pathogenesis. Therefore, scientists have been trying to discover the molecular biomarkers and genetic pathways behind these morphological changes. [4] , which may bring hope for understanding, diagnosing and treating spermatogenic dysfunction.

[0003] Recently, there is evidence that the pathogenesis of testicular spermatogenesis disorders in the above-mentioned young patients is due to the occurrence of "premature testicular aging" in young testes. In short, the testes of patients with spermatogenesis disorders of reproductive age show an aging transcriptional phenotype, which is specifically manifested in the early differential expression of aging-associated genes (SAG) and changes in aging-related biological pathways in these young testes. [5] , resulting in these originally young testicles showing characteristics similar to those of older male testicles, such as reproductive / somatic cell loss, thinning and vacuolation of the seminiferous tubules, and ultimately leading to clinical reproductive phenotypes similar to those of older men, such as decreased sperm quality, low androgen levels, and male infertility. Although this discovery explains the mechanism behind the disease to a certain extent, it only remains at the stage of discovering the pathogenesis. So far, it is unclear which specific biomarker plays a more important role in the premature changes in testicular SAG, and there has been no report on how to accurately identify and diagnose premature aging of testicles with spermatogenic disorders of reproductive age, and potential therapeutic targets in the future. [6] . Summary of the invention

[0004] The present invention is based on the above problems. The current study was conducted using data from aged testes and young testes with spermatogenesis disorders to identify key aging-related biomarkers for premature changes in testicular aging-related genes in spermatogenesis disorders of reproductive age. We further verified the changes in the expression of key testicular SAG biomarkers, analyzed its correlation with clinical, pathological, therapeutic and immune patterns, and verified our findings at the single-cell sequencing and animal model levels. We hope that this study will provide new ideas for the research, diagnosis and treatment of testicular aging, spermatogenesis disorders, especially NOA.

[0005] The results of the study found that two testicular SAGs (anti-aging effects) RUVBL2 and ZDHHC3 were downregulated in both aged testes and young testes with spermatogenesis disorders, while one testicular SAG (pro-aging effects) RPS14 was upregulated in both aged testes and young testes with spermatogenesis disorders. Although all three genes can be considered as potential qualified biomarkers, the present invention is more interested in RPS14 and believes that it is more promising because, in terms of future clinical applications, molecules that are upregulated in disease states are easier to detect and easier to use for targeted therapy. Therefore, upregulated RPS14 has greater potential to become a diagnostic marker and therapeutic target. RPS14 is identified here as an important biomarker for premature changes in testicular SAG in patients with spermatogenesis disorders of reproductive age, and is further analyzed in the following.

[0006] The validation results of different data sets showed that RPS14 had a large area under the curve (AUCs) in the receiver operating characteristic curve (ROC) for distinguishing whether testicular tissue contained sperm (all AUCs were > 0.7), which indicated that this biomarker may be used as a predictor of sperm retrieval success in testicular sperm retrieval surgery. The actual testicular tissue test results of spermatogenic dysfunction also showed that the expression level of RPS14 mRNA in testis with spermatogenic dysfunction during childbearing age was significantly increased, further confirming our findings.

[0007] Based on the above research, the specific technical solutions of the present invention are as follows:

[0008] The first aspect of the present invention provides the use of RPS14 as a marker for premature testicular aging in spermatogenesis-impaired males of childbearing age.

[0009] The second aspect of the present invention provides the use of a reagent for detecting the expression level of RPS14 in the preparation of a diagnostic kit for premature testicular aging in spermatogenesis disorders in males of childbearing age.

[0010] Preferably, the diagnostic kit comprises a reagent for detecting the content of RPS14 in a biological sample.

[0011] Further preferably, the reagent for detecting the content of RPS14 in a biological sample is selected from PCR primers with detection specificity for RPS14.

[0012] The PCR primers with detection specificity for RPS14 are as follows:

[0013]

[0014] Preferably, the biological sample is selected from a testicular tissue sample of the test subject.

[0015] The third aspect of the present invention provides a diagnostic kit for spermatogenesis disorders and premature testicular aging in males of childbearing age, the kit comprising a reagent for detecting the content of RPS14 in a biological sample.

[0016] Specifically, the diagnostic kit is composed of a reverse transcription system, a primer system and an amplification system, and the primer system includes the PCR primers shown in SEQ ID NOs. 1 to 4 above.

[0017] In a fourth aspect, the present invention provides a method for detecting premature testicular aging in spermatogenesis disorder in males of childbearing age using the above-mentioned diagnostic kit, as follows:

[0018] A. Extraction of total RNA from testicular tissue samples obtained by testicular sperm retrieval (TESE) or microtesticular sperm retrieval (mTESE);

[0019] B. Reverse transcription of the total RNA in step A to obtain cDNA;

[0020] C. The copy number of RPS14 was quantitatively detected using RT-qPCR technology. The primers used in the detection process are shown in SEQ ID NOs: 1 to 4.

[0021] The data were processed using R studio (v4.1.0 / 4.1.1) or GraphPad Prism (v9.2.0) and expressed as mean ± standard deviation.

[0022] Beneficial protection and effects of the present invention:

[0023] The present invention uses two testicular single-cell transcriptome sequencing (scRNA-seq) datasets, three testicular gene chip datasets, and testicular tissues from naturally aged mice, aged men, and patients with spermatogenesis disorders of reproductive age to identify biomarkers of premature changes in testicular SAG in men with spermatogenesis disorders of reproductive age (i.e., premature testicular aging in spermatogenesis disorders of reproductive age) and analyze their role in testicular spermatogenesis. The results showed that RPS14, as a SAG and pro-aging gene upregulated in aged testes, is an important biomarker of premature aging changes in young spermatogenesis disorders; RPS14 is also significantly upregulated in the testes of young patients with spermatogenesis disorders. Importantly, RPS14 was significantly correlated with testicular Johnsen scores and FSH levels (all p<0.05), and the receiver operating characteristic (ROC) curve revealed the potential predictive value of this biomarker in testicular sperm retrieval surgery. In addition, RPS14, as a testicular SAG, was found to be closely associated with the testicular immune microenvironment and significantly correlated with the level of testicular mast cell infiltration (p<0.05). scRNA-seq analysis and immunofluorescence staining showed that the expression pattern and distribution of RPS14 in naturally aged testes and reproductive-age testes with spermatogenesis disorders had certain similarities. At the same time, the ribosomal pathway may be the core mechanism by which this gene regulates testicular cell function. Therefore, as a testicular SAG, RPS14 has been shown to be an aging-related biomarker that may be involved in the pathogenesis of spermatogenesis disorders in young patients. This finding provides a potential diagnostic marker and therapeutic target for young patients with male infertility.

[0024] In terms of technology, the detection of RPS14 is essentially a quantitative PCR test for organ tissues, which is easy to operate, sensitive, specific, and highly repeatable. It is now increasingly used in clinical testing technology. The basic detection method we use is RT-qPCR, which has been proven to be a highly sensitive and accurate detection method in modern laboratory diagnostics. The test technology is already very mature, and we use the standard curve quantification method in this technology, which can accurately quantify the characteristic nucleic acid molecules in various samples.

[0025] In addition, the expression of the indicator RPS14 involved in the present invention in aged testicular tissue and testicular tissue of reproductive-age spermatogenesis disorder was significantly upregulated, and the difference was statistically significant (P<0.05). It has high clinical reference value and credibility, and is an effective supplement to the current detection methods. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1ScRNA-seq analysis to identify testicular SAGs: (A) UMAP map integrating all testicular cell populations of 12 samples (including 4 young testes and 8 old testes, data from GSE182786 dataset); (B) Expression profile of each testicular cell type marker; (C) Proportion of different cell types in each testicular sample; (D) DEGs of old testes compared with young testes; (E) KEGG enrichment analysis results of DEGs in old testes (top 20 pathways ranked according to p-value); (F) Intersection of up-regulated DEGs and 866 SAGs (downloaded from cellAge database); (G) Intersection of down-regulated DEGs and 866 SAGs (downloaded from cellAge database).

[0027] Figure 2 : Identification of RPS14 as a biomarker for premature changes in testicular SAG in young patients with spermatogenesis: (A) DEGs of spermatogenic testes (compared with control testes) in the discovery dataset; (B) GO-BP enrichment analysis results of spermatogenic testis DEGs (top 7 pathways ranked by p-value); (C) GO-CC enrichment analysis results of spermatogenic testis DEGs (top 7 pathways ranked by p-value); (D) GO-MF enrichment analysis results of spermatogenic testis DEGs (top 6 pathways ranked by p-value); (E) The intersection of six gene lists (① up-regulated testicular SAG; ② down-regulated testicular SAG; ③ up-regulated DEGs in the discovery dataset; ④ down-regulated DEGs in the discovery dataset; ⑤ pro-aging genes; ⑥ anti-aging genes), with the arrow pointing to the location of RPS14.

[0028] Figure 3 : Validation of RPS14 expression changes: (A) Internal validation of RPS14 expression differences between the control group and the spermatogenic dysfunction group (based on the discovery dataset), **p<0.01; (B) External validation of RPS14 expression differences between the control group and the spermatogenic dysfunction group (based on the validation dataset GSE4797), **p<0.01; (C) External validation of RPS14 expression differences between the control group and the spermatogenic dysfunction group (based on the validation dataset E-TABM-1214), ***p<0.001; (D) Immunohistochemical staining of RPS14 in a 26-year-old testis; (E) Immunohistochemical staining of RPS14 in a 56-year-old testis. Note: The original images of immunohistochemical staining in this figure are from the HPA database (https: / / www.proteinatlas.org).

[0029] Figure 4:Exploration of the relationship between RPS14 and testicular spermatogenesis: (A) The difference in RPS14 expression levels between different pathological states of the testis in the dataset was found; (B) The difference in RPS14 expression levels in testis with different pathological states in the validation dataset GSE4797; (C) The difference in RPS14 expression levels between different pathological states of the testis in the validation dataset E-TABM-1214, for (A)-(C), *p<0.05; **p<0.001; ****p<0.0001; black asterisks indicate the results of the Kruskal-Wallis test, and red asterisks indicate the results of the multiple comparison test. (D) The Spearman correlation between RPS14 expression levels and JS in the dataset was found. For this dataset, the control samples were deleted when calculating JS. (E) The Spearman correlation between RPS14 expression levels and JS in the validation dataset GSE4797; (F) The Spearman correlation between RPS14 expression levels and JS in the validation dataset E-TABM-1214. Note: JS refers to Johnsen score or modified Johnsen score.

[0030] Figure 5 : Exploration of the relationship between RPS14 and the clinical characteristics of patients and the testicular immune microenvironment: (A) Spearman correlation between RPS14 and the level of follicle stimulating hormone (FSH) in patients; (B) Spearman correlation between RPS14 levels and the GSVA scores of the two pathways "HPAbnormal CirculatingAndrogen Level" and "HallmarkSpermatogenesis" in three datasets (one discovery dataset and two validation datasets). Gray indicates p>0.05, light indicates p<0.05, but |Rho|<0.5; (C) The receiver operating characteristic curve (ROC) shows the ability of RPS14 to identify testicular samples containing sperm (JS≥8) in three chip datasets; (D) The radar chart shows the Spearman correlation Rho value between the testicular mast cell / macrophage ssGSEA score and the RPS14 expression level in the three chip datasets; (E) Testicular immune protein-protein interaction network (tiPPI) based on RPS14.

[0031] Figure 6: scRNA-seq analysis of RPS14 in aged testes and testes with spermatogenesis impairment at reproductive age: (A) Violin plots showing the expression of RPS14 in scRNA-seq data of aged and young testes, **** corrected p<0.0001; (B) Characteristic graph of RPS14 expression in aged and young testes; (C) Comparison of RPS14 expression levels in each cell type in aged testes with the same type of cells in young testes, ** corrected p<0.01; *** corrected p<0.001; **** corrected p <0.0001; red asterisks indicate significant upregulation in aged testes; blue asterisks indicate significant downregulation in aged testes; (D) KEGG enrichment analysis results based on DEGs of aged PTM cells (compared with young testicular PTM cells) (top 20 pathways ranked according to p-value); (E) UMAP plot integrating all testicular cells in six scRNA-seq testicular samples (three control samples and three young spermatogenic dysfunction samples, data from GSE149512); (F) Expression profile of marker genes for each testicular cell type. (G) Proportion of different cell types in each testicular sample; (H) Differential expression of RPS14 in scRNA-seq samples of control and spermatogenic dysfunction (disease) groups. **** corrected p<0.0001; (I) Comparison of RPS14 expression levels in endothelial cells, VSM cells and PTM cells of the testis of the spermatogenic dysfunction (disease) group with the same type of testicular cells of the control group, * corrected p<0.05; **** corrected p<0.0001; Red asterisks indicate significant upregulation in the disease group; (J) KEGG enrichment analysis results based on DEGs of PTM cells of spermatogenic dysfunction (compared with PTM cells of the testis of the control group). Note: VSM cells refer to vascular smooth muscle cells; PTM cells refer to peritubular myoid cells.

[0032] Figure 7:Detection of the expression pattern of RPS14 in different testicular tissues: (A) RT-qPCR detection of the changes in the testicular RPS14 mRNA level in patients with spermatogenesis disorders of reproductive age, *p<0.05. (B) HE staining of testicular tissue of 18-month-old mice; (C) HE staining of testicular tissue of 62-year-old men; (D) HE staining of testicular tissue of 28-year-old patients with spermatogenesis disorders of reproductive age; (E)-(G) Immunofluorescence staining shows RPS14 (green fluorescence) in testicular endothelial cells (E), PTM cells (F) or VSM cells (G) of aged mice; red fluorescence indicates PECAM1 (E) or α-SMA (F and G), and blue fluorescence indicates cell nuclei (DAPI staining); white arrows indicate typical double-stained cells; (H)-(J) Immunofluorescence staining shows testicular endothelial cells (H), PT cells (F) or VSM cells (G) of aged men. RPS14 (green fluorescence) in M ​​cells (I) or VSM cells (J); red fluorescence indicates PECAM1 (H) or α-SMA (I and J), and blue fluorescence indicates cell nuclei (DAPI staining); white arrows indicate typical double-stained cells; (K)-(M) Immunofluorescence staining shows RPS14 (green fluorescence) in testicular endothelial cells (K), PTM cells (L), or VSM cells (M) of patients with spermatogenesis disorders of reproductive age; red fluorescence indicates PECAM1 (K) or α-SMA (L and M), and blue fluorescence indicates cell nuclei (DAPI staining); white arrows indicate typical double-stained cells. DETAILED DESCRIPTION

[0033] The present invention is further described below with examples, but should not be construed as limiting the present invention. The examples do not include a detailed description of conventional methods, which are well known to those skilled in the art and are described in many publications.

[0034] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention, and the preferred implementation methods and materials described in the specific implementation methods are for demonstration purposes only.

[0035] 1. Experimental Methods

[0036] 1. Data collection and processing

[0037] 1.1 Data Collection

[0038] The SAG gene list was retrieved from the cellAge database (access date: 2023-11-07), which contains 866 non-repeated aging-related genes. For non-single-cell data, a discovery dataset GSE45885 (including 4 controls and 27 testicular spermatogenesis samples) and a validation dataset GSE4797 (including 12 controls and 16 testicular spermatogenesis samples) were downloaded from the GEO database (https: / / www.ncbi.nlm.nih.gov / geo / ), and we also downloaded another validation dataset E-TABM-1214 (only adult testicular sample data, including 8 controls and 30 testicular spermatogenesis samples) from the ArrayExpress database (https: / / www.ebi.ac.uk / arrayexpress / ).

[0039] As for single-cell sequencing data, this paper uses two scRNA-seq datasets in the GEO database, including GSE182786 and GSE149512. GSE182786 consists of testicular specimens from 4 normal young testes and 8 elderly men (≥62 years old); for GSE149512, in order to reduce the bias caused by different library construction platforms, we only included three control groups (GSM4504191 / GSM4504192 / GSM4504193) and three spermatogenic disorder samples sequenced using the BD Rhapsody platform (GSM45041995 / GSM4504196 / GSM450419).

[0040] All clinical and pathological information of patients involved in all the above datasets were collected synchronously when downloading data from GEO / ArrayExpress. It is worth emphasizing that in the spermatogenic dysfunction samples included in GSE45885, E-TABM-1214, and GSE149512, the age of all patients was ≤46 years old. For the 16 spermatogenic dysfunction samples in GSE4797, although the original dataset did not provide the specific age of each sample, the average age (± standard deviation) of each subgroup was 34.7±3.9 (JS=8), 32.5±7.6 (JS=5), or 30.3±7.0 (JS=2), which was also very young. Therefore, we can conclude that all the spermatogenic dysfunction samples we included were from men of childbearing age.

[0041] 1.2 Chip data processing

[0042] The Oligo package (v1.56.0) was used to read the raw files of the discovery dataset GSE45885, and the data were normalized by the rma function. The probe names were converted to gene symbols using hubene10sttranscriptcluster.db (v8.8.0). If the gene symbols were repeated, the average expression was calculated. Finally, the gene matrix was finally normalized using the normalizeBetweenArrays function of the limma package (v3.48.1). The raw files of the validation dataset E-TABM-1214 (all 47 samples) were read using the Affy package (v1.70.0), and the data were also normalized by the rma function, where hgu133plus2.db (v3.13.0) was used to convert the probe names to gene symbols. The average expression and normalization matrix were then obtained in the same way. After data processing, we selected the data of 38 adult samples for further analysis. The Codelink package (v1.60.0) was used to read the raw files of the validation dataset GSE4797, and then the data was corrected by codCorrect (method = "normexp", normexp.method = "rma") and normalized by codNormalize (method = "quantile"). The method used for gene annotation here is consistent with that reported previously (https: / / support.bioconductor.org / p / 68532 / #68849) and implemented using the h20kcod.db package (v3.4.0). Since GSE4797 has multiple missing values, we deleted the rows with more than 20% missing values ​​and supplemented the other missing values ​​with the k-Nearest Neighbor (KNN) method. The following data processing steps for GSE4797 are the same as those done in the discovery dataset.

[0043] 1.3 Single-cell RNA-seq data processing

[0044] For the young / old testis dataset (GSE182786), we downloaded the UMI count tables of all samples and constructed 12 separate Seurat objects using the Seurat package (v4.1). Cells were filtered in this dataset based on the following criteria: total number of genes expressed: 800 to 9000, total UMI counts: less than 35000, and proportion of mitochondrial gene expression <50%. After data normalization, the 12 samples sequenced on the 10xGenomics platform were considered as 12 independent batches, and batch correction was performed for different batches using the IntegrateData function. For GSE149512, we used the UMI count tables of three control samples and three spermatogenic dysfunction samples to construct Seurat objects. Cells were filtered in this dataset based on the following criteria: total number of genes expressed: 500 to 9000, total UMI counts: less than 35000, and proportion of mitochondrial gene expression <40%. As previous literature indicated that the three control samples and three disease samples should be considered as two independent batches, we created two separate Seurat objects for these two batches. Batch correction for the two batches was also performed using the IntegrateData function. For the above two scRNA-seq datasets, after processing with the ScaleData function, they were further processed with the RunPCA function. Next, the SNN graph was established using the FindNeighbors function using 30 principal components (PCs). The FindClusters function was used to identify cell populations (using a resolution of 0.2). Based on the 30 PCs, UMA was used to reduce the dimensionality and visualize the cell populations. Next, cell annotation was performed based on previously reported cell markers, and the FeaturePlot function of Seurat was used to show the distribution of a gene in different cell populations, and the VlnPlot function was used to show the expression of specific genes in different groups or cell types.

[0045] 2. Calculation and enrichment analysis of differentially expressed genes (DEGs)

[0046] For scRNA-seq datasets, the DEGs between two specified groups (e.g., old and young groups) were obtained by the Findmarkers function in Seurat, and |avg_log2FC|>0.2 and p_val_adj<0.05 were set as the thresholds for calculating DEGs in scRNA-seq data analysis. If DEGs were calculated between "A+ cells" and "A- cells" (A refers to a certain gene) groups, A+ (A positive) was defined as "A value>0", while A- (A negative) was defined as "A value = 0". For chip data analysis, limma (v3.48.1) was used to calculate the DEGs between the control group and the spermatogenic dysfunction group in the discovery dataset (corrected p<0.05, |logFC|>0.5), and pheatmap (v1.0.12) was used to draw heat maps to visualize the DEGs. Afterwards, DEGs obtained from scRNA-seq analysis were subjected to KEGG enrichment analysis using clusterProfiler (v4.0.5) package, and the top 20 enriched pathways (sorted by pvalues) were displayed using bar charts. DEGs obtained from chip analysis were subjected to GO enrichment analysis using clusterProfiler [divided into three parts: biological process (GO-BP), cellular component (GO-CC), and molecular function (GO-MF)], and the p cutoff value was set to 0.05. GOplot (v1.0.2) was used to visualize the highly significant results.

[0047] 3. Identification of testicular SAG in patients with spermatogenic dysfunction and identification of biomarkers for premature changes in testicular SAG

[0048] First, the 866 SAGs were intersected with the up-regulated and down-regulated DEGs (old group vs young group) obtained by scRNA-seq analysis of the GSE182786 single-cell dataset. The intersection genes were the SAGs differentially expressed in the aged testis, so they were defined as testicular SAGs. VennDiagram (v1.6.20) was used to draw a venn diagram showing the intersection. Secondly, we further obtained the intersection genes of six gene lists (① up-regulated testicular SAGs; ② down-regulated testicular SAGs; ③ up-regulated DEGs in the discovery dataset; ④ down-regulated DEGs in the discovery dataset; ⑤ aging-promoting genes; ⑥ aging-suppressing genes) to identify aging-related biomarkers for premature changes in testicular SAGs in reproductive-age spermatogenesis disorders. Among them, the information of aging-promoting genes / aging-suppressing genes was also obtained from the cellAge database. UpSetR (v1.4.0) was used to display the intersection of the above six gene lists.

[0049] 4. Internal and External Validation of Identified Biomarker Expression Levels

[0050] The expression values ​​of testicular SAG premature changes biomarker genes in spermatogenic dysfunction testes of reproductive age were extracted from the discovery dataset GSE45885 (internal validation) and two validation datasets GSE4797 / E-TABMM-1214 (external validation), and their expression differences between normal spermatogenesis (control group) and spermatogenic dysfunction patients of reproductive age were verified. In addition, the protein expression of biomarkers in testes of different ages was verified using testicular immunohistochemistry (IHC) sections obtained from the Human Protein Atlas (HPA) database (https: / / www.proteinatlas.org / ).

[0051] 5. Study on the relationship between this biomarker and clinical pathological characteristics in patients with spermatogenesis disorders

[0052] Both the discovery dataset and the two validation datasets were further used to explore the relationship between the identified biomarkers and the pathological state of the testis. Specifically, the spermatogenic state of the testis is basically divided into four pathological types, including "normal spermatogenesis" (JS10), "hypospermatogenesis" (JS 8-9), "spermatogenesis block" (JS 3-7), and "Sertoli cell-only syndrome" (SCOS) (JS2). It is necessary to specially explain one sample in the E-TABM-1214 dataset, with a JS score of 1, and its pathological type belongs to "seminal tubule sclerosis". We detected the difference in the expression level of this biomarker gene under different pathological states. In addition, the spearman correlation between its expression and JS was calculated. According to the definition of JS, a score of 8 is the watershed of the presence or absence of mature spermatids (also called testicular sperm), which suggests that sperm can definitely be obtained in testicular sperm retrieval surgery in testicular tissue samples with a JS score ≥8. Therefore, we used the receiver operating characteristic (ROC) curve to preliminarily demonstrate the efficacy of this biomarker in predicting the success rate of sperm retrieval surgery. In addition, the E-TABM-1214 dataset was also used to detect the relationship between blood follicle-stimulating hormone (FSH) levels and the expression levels of the biomarker (samples with FSH records of 0 were not included in this analysis). For one patient in E-TABM-1214, there were three biological replicates of different samples, so the same FSH level was used for the calculation of these three samples. In addition, the GSVA scores of the "HP abnormal circulatingandrogen level" and "Hallmark spermatogenesis" pathways were calculated by the GSVA software package (v1.40.1) (both downloaded from the MSigDB database). Then, the correlation between the GSVA scores of these two pathways and the expression of the biomarker was detected in all three chip datasets.

[0053] 6. Analysis of testicular mast cell / macrophage infiltration and establishment of biomarker-related testicular immune protein-protein interaction network

[0054] We used the well-known Bindea 24 immune cell gene signature (downloaded from the paper of Senbabaoglu et al.) for immune cell infiltration analysis. First, ssGSEA analysis was performed based on the Bindea 24 immune cell gene signature using the GSVA package. Since testicular mast cells and macrophages are the two largest immune cell populations in the testis and are considered to be significantly associated with spermatogenesis, we extracted the ssGSEA scores of mast cells and macrophages (reflecting the infiltration levels of testicular mast cells and macrophages) for further study. We used ggradar (v0.2) to draw radar charts to visualize the spearman correlation between the expression levels of our identified biomarkers and testicular mast cell / macrophage infiltration. In addition, we downloaded a common immune gene list from the ImmPort database (list update time: July 2020). Then the immune gene list with deduplicated gene names was intersected with the gene lists of the discovery dataset and the two validation datasets, respectively, to obtain three intersections, and the shared genes of these three intersection gene lists were retrieved. These shared immune genes were considered as commonly expressed immune genes in the testis. Subsequently, we calculated the spearman correlation between the screened biomarkers and the above commonly expressed testicular immune genes, and used "|rho|>0.5&p<0.05" as the screening criteria to eliminate immune genes with low correlation with biomarkers in the discovery dataset and the two validation datasets. In all three datasets, only immune genes that simultaneously satisfied "|rho|>0.5 and p<0.05" were used to construct the testicular immune protein-protein interaction network (tiPPI) together with the identified biomarkers (the network was constructed using the STRING website and Cytoscape (v3.7.2) software).

[0055] 7. Natural Aging Mouse Model and Testis Sample Collection

[0056] A total of four naturally aged male wild-type C57BL / 6 mice were used in this study. These animals were generously donated by the laboratory of the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, and were sacrificed at the age of 18 months of natural aging. After the mice were sacrificed, their testicular tissues were quickly collected. For each mouse, the testicular tissue was fixed in animal testicular tissue fixative (#G1121, Servicebio, China) for 24 hours and then embedded in paraffin. The fixed tissue was stained with hematoxylin-eosin (HE) to evaluate the histopathological status of the testis. The paraffin-embedded tissue will also be used for further experiments.

[0057] 8. Patients, sperm retrieval, and testicular sample collection

[0058] This study was approved by the Ethics Committee of Renji Hospital, Shanghai Jiao Tong University School of Medicine, and written informed consent for sample donation was obtained from all included patients. We recruited a total of 46 sample donors who underwent testicular sperm retrieval (TESE) or micro-TESE in the Department of Reproductive Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine (excluding patients with abnormal karyotype). During sperm retrieval, experienced andrologists obtained fresh testicular tissue samples from sample donors and quickly fixed or frozen them. Detailed information on tissue samples and their uses is listed in Table 1. Except for one sample from an elderly man, all other patients were of reproductive age. Among them, samples from NOA patients were pathologically confirmed (HE staining) to have spermatogenesis disorders, so they were “reproductive-age spermatogenesis disorders patients”. Because it is very difficult to collect testicular tissue from men with normal fertility, we used testicular samples from patients with obstructive azoospermia (OA) with pathologically confirmed normal spermatogenesis (HE staining) as controls. In addition, since the reproductive needs of the elderly are very limited, we only collected testicular samples from a 62-year-old male who underwent TESE surgery in our center as a representative of elderly testicular samples. Frozen or paraffin-embedded testicular tissues were used for further experiments.

[0059] Table 1. Information of testicular tissue samples from patients used in this study

[0060]

[0061] 9. Real-time quantitative polymerase chain reaction (RT-qPCR)

[0062] Frozen testicular tissue samples were ground and total RNA of the tissue was extracted using RNAiso Plus kit (#9109, Takara, Japan) according to the manufacturer's instructions. Then, RNA was reverse transcribed into cDNA using HiScript IV RT SuperMix kit (#R423-01, Vazyme, China). Next, RT-qPCR was performed using LightCycler (LC480; Roche, USA) using ChamQ Blue SYBR qPCR Master Mix kit (#Q312-02, Vazyme, China). The primer sequences used for human RPS14 gene amplification were (forward) 5'-CTTGCCATGCGGCTGAGTA-3' and (reverse) 5'-TCACTAACCTACCAGCCA-3'. The expression level of RPS14 was standardized using the internal reference gene GAPDH, and its primer sequences were (forward) 5'-GGAGGCGAGAGATCCCAAAT-3' and (reverse) 5'-GGCTGTTGTGTCATGG-3'. Each sample was loaded six times for testing. -ΔΔCt The relative quantification of RPS14 was calculated by the PCR.

[0063] 10. Immunofluorescence double staining (IF) based on tyramide signal amplification (TSA) technology

[0064] The TSA-based double-staining IF method used in our study has been described in previous studies. Briefly, paraffin-embedded specimens of testicular tissue were sectioned and dewaxed to water. Next, the sections were treated with Tris-EDTA (ph 8.0, #G1206, Servicebio, China) in a microwave oven for antigen retrieval. To block nonspecific binding, the sections were treated with 3% bovine serum albumin (BSA) for 30 min at room temperature. Then, the sections were incubated with anti-RPS14 antibody (1:1000, #A6727, ABclonal, China) at 4°C overnight and then washed 3 times with PBS. The sections were treated with HRP-labeled secondary antibody (1:500, #GB23303, Servicebio, China) at room temperature for 50 min. Then, FITC-Tyramide (1:500) (#G1222, Servicebio., China) was added to the sections and reacted for 10 min at room temperature to amplify the tyramide signal, followed by TBST washing 3 times. Subsequently, the sections were treated with Tris-EDTA (ph 8.0, #G1206, Servicebio, China) by microwave heating to remove the first and second antibodies bound to the tissue. After that, the sections were blocked again with 3% BSA and incubated with anti-α-SMA (1:200, #AF1032, Affinity, China) or anti-PECAM1 (1:100, #A4900, ABclonal, China) primary antibodies at 4°C overnight, and then incubated with Cy3-labeled secondary antibodies (1:300, #GB21303, Servicebio, China) at room temperature for 50 minutes. Then, the sections were treated with an autofluorescence quencher (#G1221, Servicebio, China) for 5 minutes. DAPI dye was used for nuclear staining. Finally, the slides were sealed with anti-quenching sealing fluid (#G1401, Servicebio, China) and the sections were scanned with a digital slide scanner (#Pannoramic MIDI, 3DHISTECH, Hungary).

[0065] 11. Statistical Analysis

[0066] Data are presented as mean ± SD. Mann-Whitney test and Kruskal-Wallis test were used to compare data between two groups or between three or more groups, respectively. For comparisons between three or more groups, Dunn's test was used for post hoc test. Spearman correlation was used for correlation analysis. For comparisons between groups in scRNA-seq analysis, we used the Wilcoxon rank sum test with bonferroni correction (in Findmarkers function). Statistical analysis in this study was performed using R studio (v4.1.0 / 4.1.1) or GraphPad Prism (v9.2.0). P < 0.05 was considered statistically significant.

[0067] 2. Experimental Results

[0068] 1. Identification of differentially expressed SAGs in aged testes

[0069] For the GSE182786 dataset, after filtering, a total of 42,989 cells from 12 biological samples (4 young testes and 8 old testes) were included in this study. In brief, we used classical and some newly reported cell markers ( Figure 1 B), we annotated three major spermatogenic cell populations, including “spermatogonial stem cells and spermatogonia (SSC&SPG)”, “spermatocytes (SPC)”, and “spermatids”, while we annotated somatic cell populations, including “sustaining cells”, “interstitial cells”, “peritubular myoid cells (PTM cells)”, “vascular smooth muscle cells (VSM cells)”, “endothelial cells”, and “macrophages” ( Figure 1 A). Although all of the elderly patients had fathered offspring when they were young, their spermatogenesis was not the same. For some samples, the proportions of different germ cells were very similar to those of the young control samples, while for other elderly samples, spermatogenesis was significantly reduced ( Figure 1 C). A total of 1257 genes were identified as DEGs between old and young testes ( Figure 1 D), enrichment analysis found that the above DEGs were enriched in the cell senescence pathway ( Figure 1 E). Interestingly, some ribosome-related genes, such as RPS26, RPS8, etc., were significantly upregulated in aged testes ( Figure 1 D), and the ribosome pathway ranked top in the enrichment analysis results ( Figure 1 E), suggesting that ribosomes may play an important role in testicular aging. Although SAGs have been widely reported, not all SAGs play a role in the testis. Therefore, we decided to explore which SAGs actually change in testicular aging. In the aged testis, a total of 58 SAGs were found to be upregulated ( Figure 1F), while 24 SAGs were downregulated ( Figure 1 G) These 82 SAGs differentially expressed in aged testis were defined as “testis SAGs” in this study, and they may be involved in the testicular aging process.

[0070] 2. Identification of RPS14 as an important biomarker for premature changes in testicular SAG in patients with spermatogenic dysfunction of reproductive age

[0071] A total of 1919 DEGs were identified between normal testes (control group) and spermatogenic testis samples of reproductive age (spermatogenic dysfunction group) in the GSE45885 dataset, including 892 up-regulated and 1027 down-regulated genes ( Figure 2 A). All these DEGs were mostly enriched in pathways related to sperm formation and motility, such as (GO-BP) “microtubule-based movement” ( Figure 2 B), (GO-CC) "motile cilium" ( Figure 2 C) and (GO-MF) “ATPase activity” ( Figure 2 D). Based on the fact that the testes of young spermatogenic patients show premature aging processes (especially transcriptional phenotypes), we tried to find biomarkers that could represent premature changes in testicular SAG in spermatogenic disorders of reproductive age. In summary, the biomarker we need should have the following characteristics: ① It should be testicular SAG and differentially expressed in testes of spermatogenic disorders of reproductive age; ② Its expression change trend in aged testes and testes of spermatogenic disorders of reproductive age should be the same; ③ If upregulated, it should be "pro-aging SAG", and if downregulated, it should be "anti-aging SAG" (in other words, the phenotype and gene function should be consistent, which makes it easier to do further research).

[0072] The results showed that the Upset graph showed that two testicular SAGs (anti-aging) RUVBL2 and ZDHHC3 were downregulated in both aged testes and young spermatogenic testes, while one testicular SAG (pro-aging) RPS14 was upregulated in both aged testes and young spermatogenic testes ( Figure 2 E). Although all three genes can be considered as potential qualifying biomarkers, we are more interested in RPS14 and consider it more promising. In terms of future clinical applications, molecules that are upregulated in disease states are easier to detect and more easily targeted for therapy. Therefore, from a physician's perspective, we believe that upregulated RPS14 (compared to the other two downregulated biomarkers) has greater potential to become a diagnostic marker and therapeutic target. Therefore, RPS14 is identified here as an important biomarker for premature changes in testicular SAG in patients with spermatogenic disorders of reproductive age and is further analyzed next.

[0073] 3. Internal and External Validation of RPS14 Expression Changes

[0074] The discovery dataset GSE45885 was used for internal validation of RPS14 expression changes. The results showed that RPS14 was significantly upregulated in the testicular samples of spermatogenic dysfunction in reproductive age of GSE45885 (p<0.01) ( Figure 3 A). Next, we used two validation datasets for external validation. In both validation datasets, RPS14 still showed an increasing trend in the spermatogenesis disorder group ( Figure 3 B, p < 0.01; Figure 3 C, p<0.001). We then used IHC-stained sections in the HPA database to verify the protein expression pattern of RPS14 and found that in young testes (26 years old), RPS14 protein showed moderate expression intensity ( Figure 3 D) RPS14 is distributed in cells inside and outside the seminiferous tubules ( Figure 3 D). Meanwhile, a significant enhancement of RPS14 staining can be observed in older testes (56 years old) ( Figure 3 E) Although this patient was less than 60 years old, the 56-year-old testis still provides evidence that RPS14 protein is upregulated during aging.

[0075] 4. Exploring the relationship between RPS14 and spermatogenesis and testicular immune microenvironment

[0076] Since RPS14 was shown to be significantly upregulated in testes with spermatogenic dysfunction, we speculated that it may be closely related to testicular spermatogenic function. Based on the discovery dataset and two validation datasets, we found that the expression level of RPS14 showed a significant difference pattern in different pathological conditions (all p values ​​< 0.01), and gradually increased with the aggravation of spermatogenic dysfunction ( Figure 4 A, 4B, and 4C). Notably, we found that pathological states without germ cells in the seminiferous tubule lumen (including SCOS and tubular sclerosis) presented the most significant differences in RPS14 expression compared with normal spermatogenesis, but hypospermia seemed to show only a mild increase in RPS14 that did not reach statistical significance. In addition, RPS14 was negatively correlated with JS in all three datasets (all p values ​​< 0.05) ( Figure 4 D, 4E, and 4F), indicating that it may act as a spermatogenesis inhibitor in human testis. It is worth noting that we deleted the Figure 4 D found four control samples in the dataset because these four samples in the original study were derived from commercially purchased samples and had not been pathologically scored by the researchers.

[0077] In addition, the expression of RPS14 was positively correlated with the FSH level of patients (p<0.01)( Figure 5 A), positively correlated with the GSVA score of the “abnormal circulating androgen level” gene set (except GSE45885, p < 0.01) ( Figure 5 B). In addition, RPS14 expression was also negatively correlated with the GSVA score of the “spermatogenesis” gene set (p<0.01 in all three datasets) ( Figure 5 C). All the above results indicate that the expression of RPS14 is closely related to testicular spermatogenesis and endocrine regulation. Finally, we attempted to preliminarily reveal the role of the biomarker RPS14 in the treatment of spermatogenic disorders, especially NOA. We used ROC curves to evaluate whether RPS14 can identify tissue samples containing testicular sperm (JS ≥ 8). The results showed that RPS14 had large areas under the curves (AUCs) in each data set (all AUCs were > 0.7). This result suggests that this biomarker may be used as a predictor of sperm retrieval success in testicular sperm retrieval surgery, such as TESE or mTESE surgery.

[0078] The role of the testicular immune microenvironment in the human testis in non-tumor and non-autoimmune disease states has long been overlooked because the testis is a typical immune-privileged organ. But in recent years, scientists have reported that some testicular immune genes and immune cells (especially mast cells and macrophages) play an important role in the development of spermatogenic disorders. In order to explore the relationship between the biomarker RPS14 and the testicular immune microenvironment, we evaluated it from two perspectives-testicular immune cells and testicular immune molecules. First, the radar chart showed that RPS14 was significantly correlated with the infiltration levels of testicular mast cells and macrophages in the discovery dataset and the two validation datasets (p<0.05, except for macrophages in GSE4797)( Figure 5 D). Secondly, we constructed the tiPPI network including RPS14 ( Figure 5 E). The entire network contains 18 testis-expressed immune genes (including RPS14), and RPS14 was found to be deeply involved in this tiPPI network, indicating that it is closely related to testicular immune regulation. In conclusion, RPS14 was shown to be deeply involved in the testicular immune microenvironment.

[0079] 5. ScRNA-seq analysis further demonstrated the premature upregulation of the aging marker RPS14 in testes of spermatogenic dysfunction in reproductive age

[0080] Next, we used scRNA-seq analysis to further validate the expression of RPS14 and demonstrate its cell-specific expression pattern in aged testes and spermatogenic testes of reproductive age. In the scRNA-seq dataset (GSE182786) integrated from young and aged testes, the average expression level of RPS14 in aged testicular cells was significantly increased (p<0.0001) ( Figure 6 A), but its distribution and change patterns in different types of cells are different ( Figure 6 B). We found that the expression level of RPS14 was significantly increased in senescent endothelial cells, senescent VSM cells and senescent PTM cells (all p<0.001, red asterisk) ( Figure 6 C), but in other senescent cells, the expression level of this testicular SAG did not increase significantly (in some senescent cells it even decreased significantly, blue asterisk) ( Figure 6 C). These results suggest that PTM cells, VSM cells, and endothelial cells may be the main sources of RPS14 abundance in aged testes. Among these three RPS14 growth points in aged testes, PTM cells have the largest number. Therefore, we took PTM cells as an example to explore the detailed mechanism by which RPS14 is involved in the aging of these cells. We found that DEGs between "RPS14+PTM cells" and "RPS14-PTM cells" were significantly enriched in mechanistic pathways such as the "ribosome" pathway ( Figure 6 D).

[0081] In addition, since we found that RPS14 is a biomarker for premature changes in testicular SAG, the premature upregulation of RPS14 in these three cell types in spermatogenic testes of reproductive age also needs to be verified by scRNA-seq analysis. Therefore, we further analyzed another testicular scRNA-seq dataset GSE149512. As described in the methods section above, we only included six biological samples (three "normal spermatogenesis / control groups" and three young "spermatogenesis / disease groups") for integrated analysis. A total of 31,168 cells were included through filtering, and the testicular cell type identification process here is the same as that of the GSE182786 dataset ( Figure 6 E), expression patterns of some testicular cell markers such as Figure 6 F. We can notice that in this single-cell dataset, the number of germ cells in the spermatogenic dysfunction samples of reproductive age is significantly reduced ( Figure 6 G). Importantly, testicular SAG RSP14 was also significantly upregulated in spermatogenic testes of reproductive age (p<0.0001) ( Figure 6H), which further proves the premature expression of this biomarker in spermatogenic testes of reproductive age. Similar to the results of GSE182786, we also found that RPS14 was significantly upregulated in PTM cells, VSM cells and endothelial cells in young spermatogenic testes (all p<0.05) ( Figure 6 I). This result further suggests that PTM cells, VSM cells, and endothelial cells may be the most important cell types for the premature upregulation of the testicular aging-related gene RPS14 in young spermatogenic testes. Then, we also took PTM cells as an example to explore the function of RPS14. The DEGs between "RPS14+PTM cells" and "RPS14-PTM cells" were also enriched in mechanistic pathways such as the "ribosome" pathway ( Figure 6 J), which further suggests that RPS14 participates in aging and premature aging in a similar manner in PTM cells in aged testes and young spermatogenic testes.

[0082] 6. Verification of the expression and distribution of RPS14 in testicular tissue

[0083] To further confirm the premature upregulation of RPS14 expression in the testes of patients with spermatogenic dysfunction at childbearing age, we collected testicular samples from 42 patients of childbearing age who underwent sperm retrieval (including 14 controls and 28 spermatogenic dysfunction tissues) to detect changes in RPS14 expression. RT-qPCR results showed that the expression level of RPS14 mRNA in testes with spermatogenic dysfunction (at childbearing age) was significantly increased compared with that in the control group ( Figure 7 Next, in order to better demonstrate the distribution of RPS14 in endothelial cells, PTM cells, and VSM cells (i.e., to verify the results we found in scRNA-seq analysis), we used the TSA method to analyze the distribution of RPS14 in the testes of aged mice ( Figure 7 B) Testicles of elderly men ( Figure 7 C) and IF staining was performed in testes with spermatogenesis impairment during childbearing age ( Figure 7 D) The results showed that RPS14 was expressed in testicular endothelial cells ( Figure 7 E and 7H), PTM cells ( Figure 7 F and 7I) and VSM cells ( Figure 7 G and 7J). In addition, IF staining in spermatogenic testes of reproductive age showed that RPS14 was expressed in endothelial cells ( Figure 7 K), PTM cells ( Figure 7 H) and VSM cells ( Figure 7 M) were similar to those in aged testis, further confirming the findings from scRNA-seq analysis that these three cell types are important sources of RPS14 in the testis of aged and young spermatogenic men.

[0084] 3. Results and Discussion

[0085] Spermatogenesis disorder is the cause of NOA, but existing treatments are not always effective. For men of childbearing age, spermatogenesis disorder may directly lead to infertility, which not only affects reproductive health but also has adverse effects on couples' relationships. This has led scientists to conduct more in-depth research on the pathogenesis and biomarkers of spermatogenesis disorder in young men, hoping to find new therapeutic targets for them. On the other hand, although spermatogenesis is not so important for older men, scientists still found that changes in gene expression patterns and cell functions in the aging testis of older men are also harmful to spermatogenesis. Recently, the intrinsic connection between these two testicular states (spermatogenesis disorder in young men / aging testis in older men) has been revealed, that is, young spermatogenesis disorder testis shows early-onset changes in aging gene phenotypes. This suggests that early-onset changes in testicular SAG may play an important role in the pathogenesis of spermatogenesis disorder. However, so far, few studies have focused on the role of testicular SAG in spermatogenesis disorder. Here, we conducted this study to identify markers of early-onset changes in aging-related genes in spermatogenesis disorder testis of childbearing age. We found that RPS14, a testicular SAG, was significantly altered in the testes of young male spermatogenic dysfunction. We also further verified and analyzed its expression pattern in human testes and its relationship with spermatogenic function.

[0086] This invention shows for the first time that RPS14 is also upregulated in aged testes, and that PTM cells, VSM cells, and endothelial cells are important sources of testicular RPS14. Interestingly, we also found that RPS14 was significantly upregulated in young testes with spermatogenesis disorders, making it an important aging-related biomarker for premature gene expression changes in these young patients. In young testes, this upregulation was also observed in PTM cells, VSM cells, and endothelial cells. The above results suggest that RPS14 may be an important regulator of testicular aging, especially for testicular somatic cells in aged testes and young testes with spermatogenesis disorders. As a ribosomal protein, RPS14 is involved in the regulation of aging through senescence-associated ribosome development defects (SARD). This finding is consistent with the results of our enrichment analysis using RPS14+PTM cell DEGs, that is, the "ribosome" pathway ranked first.

[0087] Few studies have focused on the potential role of RPS14 in human reproductive medicine. RPS14 has been reported to be essential for early embryonic developmental competence in mice, providing limited evidence for the involvement of RPS14 in reproduction. However, the potential role of RPS14 in human spermatogenesis has long been overlooked. In this study, we first discovered a close relationship between the testicular premature aging marker RPS14 and testicular pathological (such as JS) and clinical (such as FSH levels) characteristics. These important results suggest that RPS14 may be a potential target for the treatment of spermatogenic disorders and a potential predictor of treatment efficacy. More importantly, since RPS14 is associated with premature testicular aging, it seems promising to use anti-aging treatments to repair spermatogenic disorders during reproductive age in the future, which certainly requires further studies to confirm.

[0088] Despite the characteristics of immune privilege in the testis, the testicular immune environment, including testicular immune genes and testicular immune cells, was still found to be closely related to the development of spermatogenic disorders. Notably, previous studies have found that RPS14 is significantly associated with tumor-infiltrating cells. Naturally, we speculated that this marker of testicular premature aging may also be involved in the regulation of the testicular immune environment, just as it is in tumors. As we expected, the expression level of RPS14 was significantly correlated with the infiltration levels of two testicular immune cells (mast cells and macrophages) associated with NOA. The tiPPI network showed that RPS14 could indirectly interact with some testicular immune cytokines such as IL13 or IL33 and some immune cell markers such as CD14. Therefore, testicular SAGRPS14 may impair spermatogenesis not only through premature aging mechanisms but also by interfering with the normal testicular immune microenvironment.

[0089] In summary, the present invention identified biomarkers for premature changes in testicular SAG in spermatogenic dysfunction of reproductive age (i.e., premature testicular aging of reproductive age). We identified and validated the testicular functional SAG RPS14, whose expression in both aged and young spermatogenic dysfunction testes was significantly altered and significantly correlated with the patient's clinical pathological characteristics (such as JS and FSH) and the testicular immune microenvironment. In addition, we found that the expression of this biomarker in aged and young spermatogenic dysfunction testes had obvious cell specificity, and its cellular distribution in aged and young spermatogenic dysfunction testes had similar characteristics.

[0090] The references involved in the background technology of the present invention are as follows:

[0091] 1.Sharma A,Minhas S,Dhillo WS,Jayasena CN.Male infertility due totesticular disorders.J Clin Endocrinol Metab 2021;106:e442-e459.

[0092] 2.Johnsen SG.Testicular biopsy score count--a method for registrationofspermatogenesis in human testes:normal values and results in 335hypogonadalmales.Hormones 1970;1:2-25.

[0093] 3.De Kretser DM,Holstein,A.F.Testicular biopsy and abnormal germcells.In Hafez,.In:Hafez ESE,editor.Human Semen and Fertility Regulation inMen.St.Louis:Mosby;1976.p.332-343.

[0094] 4.Cioppi F,Rosta V,Krausz C.Genetics ofAzoospermia.Int J Mol Sci2021;22.

[0095] 5.Alfano M,Tascini AS,Pederzoli F,Locatelli I,Nebuloni M,Giannese F,et al.Aging,inflammation and DNA damage in the somatic testicular niche withidiopathic germ cell aplasia.Nat Commun 2021;12:5205.

[0096] 6. Dong S, Chen C, Zhang J, Gao Y, Zeng X, Zhang X. Testicular aging, malefertility and beyond. Front Endocrinol (Lausanne) 2022;13:1012119.

[0097] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.

Claims

1. Application of reagents for detecting RPS14 expression levels in the preparation of a diagnostic kit for premature testicular aging in spermatogenesis disorders in men of childbearing age.

2. The use according to claim 1, characterized in that: The diagnostic kit comprises a reagent for detecting the expression level of RPS14 in a biological sample.

3. The use according to claim 2, characterized in that: The reagent for detecting the content of RPS14 in a biological sample is selected from PCR primers with detection specificity for RPS14, and the nucleic acid sequence of the PCR primers is shown in SEQ ID NOs. 1-4.

4. The use according to claim 2, characterized in that: The biological sample is selected from testicular tissue.

5. A diagnostic kit for premature testicular aging and spermatogenesis disorders in males of childbearing age, the kit comprising a reagent for detecting the content of RPS14 in a biological sample.

6. The diagnostic kit according to claim 5, characterized in that The diagnostic kit is composed of a reverse transcription system, a primer system and an amplification system. The primer system includes PCR primers as shown in SEQ ID NO.1-4.